Dossier
clinicaltrials
trial early
Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
Key claim: PXS-5505 is being studied in an open-label phase 1/2a dose-escalation and expansion trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in primary, post-PV, and post-ET myelofibrosis.
Abstract
This study will be an open-label phase 1/2a study to evaluate the safety and tolerability of PXS-5505 in patients with primary, postpolycythemia vera (PV) or post-essential thrombocythemia (ET) myelofibrosis.
Why this matters
PXS-5505 is being studied in an open-label phase 1/2a dose-escalation and expansion trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in primary, post-PV, and post-ET myelofibrosis.